相似文献
1
Current Progress in Therapeutic Gene Editing for Monogenic Diseases.
Mol Ther. 2016 Mar;24(3):465-74. doi: 10.1038/mt.2016.5. Epub 2016 Jan 14.
2
Recent Progress in Genome Editing Approaches for Inherited Cardiovascular Diseases.
Curr Cardiol Rep. 2018 Jun 2;20(7):58. doi: 10.1007/s11886-018-0998-3.
3
Genome editing in large animal models.
Mol Ther. 2021 Nov 3;29(11):3140-3152. doi: 10.1016/j.ymthe.2021.09.026. Epub 2021 Oct 1.
4
Genome-editing Technologies for Gene and Cell Therapy.
Mol Ther. 2016 Mar;24(3):430-46. doi: 10.1038/mt.2016.10. Epub 2016 Jan 12.
5
Therapeutic genome editing with engineered nucleases.
Hamostaseologie. 2017 Jan 31;37(1):45-52. doi: 10.5482/HAMO-16-09-0035. Epub 2017 Jan 10.
6
Gene therapy comes of age.
Science. 2018 Jan 12;359(6372). doi: 10.1126/science.aan4672.
7
The delivery challenge: fulfilling the promise of therapeutic genome editing.
Nat Biotechnol. 2020 Jul;38(7):845-855. doi: 10.1038/s41587-020-0565-5. Epub 2020 Jun 29.
8
Genome Editing Techniques and Their Therapeutic Applications.
Clin Pharmacol Ther. 2017 Jan;101(1):42-51. doi: 10.1002/cpt.542. Epub 2016 Nov 18.
9
Point: Treating Human Genetic Disease One Base Pair at a Time: The Benefits of Gene Editing.
Clin Chem. 2018 Mar;64(3):486-488. doi: 10.1373/clinchem.2017.278309.
10
Acceptance and Access to Gene Editing: Science and Our Obligations to Mankind.
Mol Ther. 2017 Jan 4;25(1):1-2. doi: 10.1016/j.ymthe.2016.12.012. Epub 2016 Dec 28.
引用本文的文献
1
The Interface of Gene Editing with Regenerative Medicine.
Engineering (Beijing). 2025 Mar;46:73-100. doi: 10.1016/j.eng.2024.10.019. Epub 2024 Nov 30.
2
Regional patterns of genetic variants in expanded carrier screening: a next-generation sequencing pilot study in Fujian Province, China.
Front Genet. 2025 May 12;16:1527228. doi: 10.3389/fgene.2025.1527228. eCollection 2025.
3
Male gamete copies to characterize genome inheritance and generate progenies.
Sci Rep. 2025 May 4;15(1):15600. doi: 10.1038/s41598-025-99188-1.
4
Plasmid Gene Therapy for Monogenic Disorders: Challenges and Perspectives.
Pharmaceutics. 2025 Jan 14;17(1):104. doi: 10.3390/pharmaceutics17010104.
5
Axonal Regeneration after Spinal Cord Injury: Molecular Mechanisms, Regulatory Pathways, and Novel Strategies.
Biology (Basel). 2024 Sep 7;13(9):703. doi: 10.3390/biology13090703.
6
In utero delivery of targeted ionizable lipid nanoparticles facilitates in vivo gene editing of hematopoietic stem cells.
Proc Natl Acad Sci U S A. 2024 Aug 6;121(32):e2400783121. doi: 10.1073/pnas.2400783121. Epub 2024 Jul 30.
7
Rapid Whole-Genome Sequencing and Clinical Management in the PICU: A Multicenter Cohort, 2016-2023.
Pediatr Crit Care Med. 2024 Aug 1;25(8):699-709. doi: 10.1097/PCC.0000000000003522. Epub 2024 Apr 26.
8
Developing a genetic testing panel for evaluation of morbidities in kidney transplant recipients.
Kidney Int. 2024 Jul;106(1):115-125. doi: 10.1016/j.kint.2024.02.021. Epub 2024 Mar 21.
9
Engineered mischarged transfer RNAs for correcting pathogenic missense mutations.
Mol Ther. 2024 Feb 7;32(2):352-371. doi: 10.1016/j.ymthe.2023.12.014. Epub 2023 Dec 16.
10
Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec.
Mol Ther Methods Clin Dev. 2023 Aug 9;30:474-483. doi: 10.1016/j.omtm.2023.08.002. eCollection 2023 Sep 14.
本文引用的文献
1
A mechanism for the suppression of homologous recombination in G1 cells.
Nature. 2015 Dec 17;528(7582):422-6. doi: 10.1038/nature16142. Epub 2015 Dec 9.
2
Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.
Cell. 2015 Oct 22;163(3):759-71. doi: 10.1016/j.cell.2015.09.038. Epub 2015 Sep 25.
3
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis.
Nature. 2015 Nov 12;527(7577):192-7. doi: 10.1038/nature15521. Epub 2015 Sep 16.
4
Functional footprinting of regulatory DNA.
Nat Methods. 2015 Oct;12(10):927-30. doi: 10.1038/nmeth.3554. Epub 2015 Aug 31.
5
Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs.
Cell Rep. 2015 Sep 1;12(9):1385-90. doi: 10.1016/j.celrep.2015.07.062. Epub 2015 Aug 20.
6
In vivo genome editing of the albumin locus as a platform for protein replacement therapy.
Blood. 2015 Oct 8;126(15):1777-84. doi: 10.1182/blood-2014-12-615492. Epub 2015 Aug 21.
7
Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9.
Cell Stem Cell. 2015 Aug 6;17(2):213-20. doi: 10.1016/j.stem.2015.07.001. Epub 2015 Jul 23.
8
Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Sci Rep. 2015 Jul 9;5:12065. doi: 10.1038/srep12065.
9
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Respir Med. 2015 Sep;3(9):684-691. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3.
10
Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model.
PLoS Genet. 2015 May 22;11(5):e1005239. doi: 10.1371/journal.pgen.1005239. eCollection 2015 May.
Zotero 插件